Scandinavian Chemotech (Q1 Review): Lean operations and clinical momentum - Redeye

Redeye provides an update following Scandinavian Chemotech’s Q1 2026 report. Sales were softer than expected, while the solid cost control continued. As a result, we have trimmed our sales estimates, while doing the same for OPEX. All in all, we arrive at a reiterated fair value range of SEK2-10, with a base case of SEK6.3.

Länk till analysen i sin helhet: https://www.redeye.se/research/1162633/scandinavian-chemotech-q1-review-lean-operations-and-clinical-momentum-drive-progress?utm_source=finwire&utm_medium=RSS